Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Protects Endothelial Function in Hypertension Through a Glucagon–Like Peptide 1–Dependent Mechanism
Authors:
- Limei LiuLLLimei Liu
- Jian LiuJLJian Liu
- Wing Tak WongWing Tak Wong
- Xiao Yu TianXTXiao Yu Tian
- Chi Wai LauCLChi Wai Lau
- Yi-Xiang WangYi-Xiang Wang
- Gang XuGXGang Xu
- Yunfei PuYPYunfei Pu
- Zhiming ZhuZZZhiming Zhu
- Aimin XuAXAimin Xu
- Karen S.L. LamKLKaren S.L. Lam
- Zhen Yu ChenZCZhen Yu Chen
- 1 September 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 60 (3) , 833-841
Abstract
Sitagliptin, a selective dipeptidyl peptidase 4 inhibitor, inhibits the inactivation and degradation of glucagon like peptide 1 (GLP-1), which is used for the treatment of type 2 diabetes mellitus. However, little is known about the role of GLP-1 in hypertension. This study investigated whether the activation of GLP-1 signaling protects endothelial function in hypertension. Two-week sitagliptin treatment (10 mg/kg per day, oral gavage) improved endothelium-dependent relaxation in renal arteries, restored renal blood flow, and reduced systolic blood pressure in spontaneously hypertensive rats. In vivo sitagliptin treatment elevated GLP-1 and GLP-1 receptor expressions, increased cAMP level, and subsequently activated protein kinase A, liver kinase B1, AMP-activated protein kinase-α and endothelial NO synthase in spontaneously hypertensive rat renal arteries. Inhibition of GLP-1 receptor, adenylyl cyclase, protein kinase A, AMP-activated protein kinase-α, or NO synthase reversed the protective effects of sitagliptin. We also demonstrate that GLP-1 receptor agonist exendin 4 in vitro treatment had similar vasoprotective effects in spontaneously hypertensive rat renal arteries and increased NO production in spontaneously hypertensive rat aortic endothelial cells. Studies using transient expressions of wild-type and dominant-negative AMP-activated protein kinase-α2 support the critical role of AMP-activated protein kinase-α in mediating the effect of GLP-1 in endothelial cells. Ex vivo exendin 4 treatment also improved endothelial function of renal arteries from hypertensive patients. Our results elucidate that upregulation of GLP-1 and related agents improve endothelial function in hypertension by restoring NO bioavailability, suggesting that GLP-1 signaling could be a therapeutic target in hypertension-related vascular events.Keywords
This publication has 42 references indexed in Scilit:
- Oxidative Stress-Dependent Cyclooxygenase-2-Derived Prostaglandin F 2α Impairs Endothelial Function in Renovascular Hypertensive RatsAntioxidants & Redox Signaling, 2012
- Protective Effect of Anthocyanins Extract from Blueberry on TNBS‐Induced IBD Model of MiceEvidence-Based Complementary and Alternative Medicine, 2011
- Further Improvement in Postprandial Glucose Control With Addition of Exenatide or Sitagliptin to Combination Therapy With Insulin Glargine and MetforminDiabetes Care, 2010
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot studyCardiovascular Diabetology, 2010
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated AngioedemaHypertension, 2009
- Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthaseCardiovascular Research, 2009
- Exendin-4 has an anti-hypertensive effect in salt-sensitive mice modelBiochemical and Biophysical Research Communications, 2009
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influxAmerican Journal of Physiology-Renal Physiology, 2005
- Computed tomography-derived intrarenal blood flow in renovascular and essential hypertensionKidney International, 1996